Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol.
Tan Boon TohDexter Kai Hao ThngNagarjun BolemBalamurugan A VellayappanBryce Wei Quan TanYating ShenSou Yen SoonYvonne Li En AngNivedh DineshKejia TeoVincent Diong Weng NgaShiong Wen LowPek Lan KhongEdward Kai-Hua ChowDean HoTseng Tsai YeoAndrea Li Ann WongPublished in: PloS one (2024)
This trial was registered on 8th September 2022 with ClinicalTrials.gov Identifier: NCT05532397.